ReviewMycoses2021
Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches.
Review in Mycoses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Guideline
- Prevalence of invasive fungal infection in critically Ill patients: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Pooled it
- Evaluation of Molecular Assays for Rapid Diagnosis of Invasive Fungal Infections: Clinical Experience with the Commercial CandID and AspID Real-Time PCR Assays in Paraguay.Journal of fungi (Basel, Switzerland) · 2026Article
- Diagnostic Failure in Invasive Fungal Infections: Causes, Clinical Consequences, and Mitigation Strategies.Journal of fungi (Basel, Switzerland) · 2026Review
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
- Epidemiology of Aspergillosis Diagnoses in US Adults Using a National EHR Database, 2013-2023.Open forum infectious diseases · 2026Article
- Primary Therapy for Invasive Aspergillosis With Triazoles or L-AmB: A Multicenter Retrospective Study.Open forum infectious diseases · 2026Article
- Multiplex on-chip detection ofFrontiers in bioengineering and biotechnology · 2026Article
- Misdiagnosis of invasive pulmonary fungal disease caused by drug-resistantFrontiers in medicine · 2026Article
- The clinical application of metagenomic next-generation sequencing for invasive pulmonary aspergillosis in neutropenic patients: a multicenter retrospective study in the ICU.Frontiers in cellular and infection microbiology · 2026Article
- The cyclase-associated protein contributes to antifungal susceptibility and virulence inEmerging microbes & infections · 2025Article
- Comparison of Omicron and respiratory virus infections in pediatric liver transplantation: Impact of perioperative identification status.Virulence · 2025Article
- Influenza-related invasive pulmonary aspergillosis in an infectious disease ward at a pulmonary referral center in Iran.BMC infectious diseases · 2025Article
- Pulmonary Aspergillosis in Immunocompromised Critically Ill Patients: Prevalence, Risk Factors, Clinical Features and Diagnosis-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- TDM-Based Approach for Properly Managing Intravenous Isavuconazole Treatment in a Complex Case Mix of Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2025Article
- Emerging Risk Factors for Invasive Pulmonary Aspergillosis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Current Challenges in the Treatment of Invasive Aspergillosis in Geriatric Patients.Journal of fungi (Basel, Switzerland) · 2025Article
- Performance of Diagnostic Algorithms in Patients With Invasive Pulmonary Aspergillosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- [S1 guideline: diagnosis and treatment of invasive pulmonary aspergillosis in critically ill/intensive care patients].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Invasive aspergillosis (IA) is an increasingly recognised phenomenon in critically ill patients in the intensive care unit, including in patients with severe influenza and severe coronavirus disease 2019 (COVID-19) infection. To date, there are no consensus criteria on how to define IA in the ICU population, although several criteria are used, including the AspICU criteria and new consensus criteria to categorise COVID-19-associated pulmonary aspergillosis (CAPA). In this review, we describe the epidemiology of IA in critically ill patients, most common definitions used to define IA in this population, and most common clinical specimens obtained for establishing a mycological diagnosis of IA in the critically ill. We also review the most common diagnostic tests used to diagnose IA in this population, and lastly discuss the most common clinical presentation and imaging findings of IA in the critically ill and discuss areas of further needed investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.